title: Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer.
abstract: BACKGROUND
  This phase II study was designed to assess the activity and tolerability of the carboplatin-paclitaxel combination, given without routine growth factor support to previously untreated patients with stage IIIB and IV non-small cell lung cancer.
  
  
  METHODS
  Sixty patients (15 stage IIIb and 45 stage IV) received paclitaxel 225 mg/ml on day 1, followed by carboplatin AUC 6 mg/ml per minute (Calvert formula) every 3 weeks. Paclitaxel was administered as a 3-h intravenous infusion followed by carboplatin over 30 min, on completion of paclitaxel administration.
  
  
  RESULTS
  The combination showed a good safety profile with Grade 4 neutropenia occurring in 31% of patients without any serious infectious episodes requiring hospitalization. Moderate to severe anemia and thrombocytopenia seldom occurred. Sensorimotor peripheral neuropathy (Grade 2-3) and myalgia (Grade 3-4) were documented in 34 and 20% of the patients, respectively. Among 59 evaluable patients, there was one complete response and 26 partial responses for an overall response rate of 46% (95% C.I.: 34-59%). With a minimum follow-up duration of 16.5 months, the median overall survival time is 52 weeks and the 1-year survival rate is 50%. Median duration of response is 20 weeks (range: 4-52) and progression-free survival is 22 weeks (range: 5-77).
  
  
  CONCLUSIONS
  In advanced NSCLC, the combination carboplatin-paclitaxel at doses of AUC 6 mg/ml per minute and 225 mg/ml every 3 weeks, is both active and relatively well-tolerated.
authors.affiliation: Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S. Luigi, Regione Gonzole 10, 10043 Orbassano, Turin, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Novello
authors.forename: L
authors.initials: L
authors.lastname: Galli
authors.forename: A
authors.initials: A
authors.lastname: Antonuzzo
authors.forename: L
authors.initials: L
authors.lastname: Crinó
authors.forename: E
authors.initials: E
authors.lastname: Pozzi
authors.forename: G
authors.initials: G
authors.lastname: Selvaggi
authors.forename: S
authors.initials: S
authors.lastname: Ricci
authors.forename: F
authors.initials: F
authors.lastname: Marrocolo
authors.forename: S
authors.initials: S
authors.lastname: Darwish
authors.forename: S
authors.initials: S
authors.lastname: Sorbolini
authors.forename: M
authors.initials: M
authors.lastname: Tonato
authors.forename: G V
authors.initials: GV
authors.lastname: Scagliotti
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D016019:Survival Analysis
chemical_list: D016190:Carboplatin; D017239:Paclitaxel